Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
Nyxoah SA (NYXH) reported Q2 2026 net revenue of €7.7 million, up from €1.3 million a year earlier, with U.S. net revenue €5.2 million, 22% higher sequentially. First-half 2026 net revenue was €14.0 million. The company secured $110 million financing, had €97.8 million cash at June 30, and guided FY2026 revenue €36-40 million and gross margin 60-62%.
How this was made
The 30-second read
Why it matters
Traders can update NYXH’s near-term fundamentals using the disclosed sequential U.S. revenue growth, the size of the newly secured financing, and the maintained full-year guidance ranges for revenue, gross margin, and operating expenses.
Market read
The combination of accelerating U.S. revenue, 100% prior-authorization approval, and a $110M financing close is a tangible catalyst set for NYXH’s commercialization and funding-risk narrative.
What to watch
The gross margin declined in the first half due to production yield issues, and operating expenses are increasing due to U.S. commercial build-out, which may offset revenue momentum before scale benefits appear.
Background
Nyxoah is commercializing Genio for obstructive sleep apnea (OSA) following FDA approval in August 2025, and this update focuses on Q2 and first-half 2026 financials plus U.S. commercialization and reimbursement progress.
Ticker impact
Nyxoah reported Q2 2026 U.S. net revenue of €5.2M, 22% sequential growth, plus updated 2026 guidance and a $110M financing close.
Moderately positive bias for NYXH, with upside sensitivity to any follow-through in U.S. account activation and prior-authorization pipeline.
Key disclosed items include sequential U.S. revenue growth, 100% prior-authorization approval, and a $110M aggregate financing with cash rising to €97.8M, which can reduce funding risk while commercialization indicators improve. However, the article also shows rising operating expenses and does not provide a new consensus-beating earnings surprise beyond the disclosed quarter and guidance range.
Market effects
Positive read-through for U.S. reimbursement-driven medtech commercialization stories, especially where prior-authorization approval rates and coding clarity are improving.
Belgium-listed biotech/medtech sentiment may improve given the disclosed U.S. traction and cash position.
Limited direct global macro impact, but international revenue growth and reimbursement clarity can influence peer sentiment in OSA treatment markets.
Counterpoint
Rising SG&A and operating loss alongside a higher U.S. revenue mix could pressure margins if production yield issues persist or if reimbursement assumptions prove optimistic.
Key entities
- companyNyxoah SA
Medical technology company focused on commercialization of Genio for OSA, reporting Q2 and first-half 2026 results and 2026 guidance.
- productGenio
Nyxoah’s OSA treatment product referenced in reimbursement and commercialization metrics.
- regulatorCMS
Proposed 2027 reimbursement increases cited for hospital outpatient and ambulatory surgical centers.
